Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer’s disease

To detect comorbidity with osteoporosis at a subclinical level, we studied concentrations of biochemical osteoporosis markers in blood plasma of subjects with mild cognitive impairment and mild Alzheimer’s disease compared to subjects with primary osteoporosis and age-matched cognitively normal controls in an explorative approach

Christian Luckhaus

2009

Scholarcy highlights

  • Previous studies revealed some comorbidity of Alzheimer’s disease and osteoporosis for advanced disease, and for the incipient conditions cognitive decline and decline of bone mineral density
  • To detect comorbidity with osteoporosis at a subclinical level, we studied concentrations of biochemical osteoporosis markers in blood plasma of subjects with mild cognitive impairment and mild Alzheimer’s disease compared to subjects with primary osteoporosis and age-matched cognitively normal controls in an explorative approach
  • Regarding disease-spanning molecular pathology we studied osteoprotegerin, a decoy receptor of RANKL and TRAIL
  • Osteoprotegerin was unchanged between patient groups and controls. 25 vitamin D plasma levels were low normal and of equal amount in all groups except for the osteoporosis group
  • Previously reported plasma level increases in Alzheimer’s disease were not observed in this study, which does not rule out subtle changes to be detected in larger samples or the possibility that other components of osteoprotegerin pathways are affected in Alzheimer’s disease

Need more features? Save interactive summary cards to your Scholarcy Library.